Document Detail


Natural history of focal moderate cardiac allograft rejection. Is treatment warranted?
MedLine Citation:
PMID:  7895355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The rate of progression and potential long-term consequences of isolated foci of moderate acute rejection (FMR) on endomyocardial biopsy (EMB) have not been defined; therefore, whether FMR necessitates augmented immunosuppression remains controversial. METHODS AND RESULTS: At our institution, recipients with EMBs having FMR, defined as one or two isolated foci of cellular infiltrates with associated myocyte damage (International Society for Heart and Lung Transplantation [ISHLT] grade 2 and a subset of grade 3A), do not routinely receive intensified immunosuppression. Accordingly, to determine the outcome of untreated FMR, we reviewed 4398 EMBs (mean, 4.4 samples each) obtained after orthotopic heart transplantation in 208 consecutive recipients maintained on triple immunosuppressive therapy. The incidence of progression versus resolution of FMR, the time interval after transplantation when FMR was detected, and the relation of untreated FMR to recipient survival were analyzed. FMR categorized as one (n = 312) or two (n = 89) foci was present in 401 EMBs (9% of total) obtained 10 days to 7.5 years after transplantation from 149 recipients (72%). EMBs with FMR resolved without treatment in 341 of 401 (85%), and only 60 of 401 (15%) progressed to higher grade rejection. EMBs that progressed occurred 7.5 +/- 7.9 months (mean +/- SD) after transplantation compared with 14.0 +/- 16.5 months after transplantation for those that resolved (P < .005). Of the 60 EMBs that progressed, 55% occurred within the first 6 months, 78% within the first year, and 97% within the first 2 years after transplantation. EMBs with two foci of FMR were no more likely to progress than those with one focus. Thirty-nine recipients experienced one (n = 25), two (n = 9), three (n = 3), or four (n = 2) episodes of FMR that progressed. One or more episodes of FMR that did not progress occurred in 110 recipients. By Kaplan-Meier analysis, survival at 1 and 5 years was similar in recipients with and those without FMR progression. CONCLUSIONS: First, untreated FMR consisting of either one or two foci has a low rate of progression. Second, progression of FMR decreases with increasing postoperative interval and becomes rare after 2 years. Last, FMR progression did not identify recipients with decreased survival.
Authors:
G L Winters; E Loh; F J Schoen
Related Documents :
16799075 - Impact of a lung transplantation donor-management protocol on lung donation and recipie...
11182015 - Assessment of quality of life in lung transplantation using a simple generic tool.
17072795 - Evolving immunosuppressive regimens for lung transplant recipients.
3150765 - The nottingham health profile as a measure of quality of life following combined heart ...
17255665 - A pilot study in sub-smas face transplantation: defining donor compatibility and assess...
3278435 - Dominant effect of histocompatibility on ten-year kidney transplant survival.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  91     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-04-21     Completed Date:  1995-04-21     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1975-80     Citation Subset:  AIM; IM    
Affiliation:
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Azathioprine / therapeutic use
Biopsy
Cyclosporine / therapeutic use
Disease Progression
Endocardium / pathology
Female
Graft Rejection / epidemiology,  pathology,  therapy*
Heart Transplantation / immunology*,  pathology
Humans
Immunosuppression*
Male
Middle Aged
Myocardium / pathology
Prednisone / therapeutic use
Survival Analysis
Time Factors
Grant Support
ID/Acronym/Agency:
HL-43364/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
446-86-6/Azathioprine; 53-03-2/Prednisone; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients ...
Next Document:  Aging and endothelial function in normotensive subjects and patients with essential hypertension.